Acceleron Pharma Inc (NASDAQ:XLRN)‘s stock had its “buy” rating reaffirmed by equities research analysts at FBR & Co in a report issued on Thursday.

XLRN has been the topic of a number of other research reports. Nomura initiated coverage on Acceleron Pharma in a research report on Wednesday, March 1st. They issued a “buy” rating on the stock. Citigroup Inc raised Acceleron Pharma from a “neutral” rating to a “buy” rating and lowered their target price for the company from $40.00 to $36.00 in a research report on Thursday, March 2nd. Zacks Investment Research raised Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 10th. JPMorgan Chase & Co. initiated coverage on Acceleron Pharma in a research report on Tuesday, March 14th. They issued a “neutral” rating and a $33.00 target price on the stock. Finally, Cann reaffirmed an “outperform” rating on shares of Acceleron Pharma in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $43.64.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) traded down 5.68% during mid-day trading on Thursday, hitting $25.56. The stock had a trading volume of 493,157 shares. The company’s market capitalization is $987.05 million. The stock’s 50-day moving average is $28.87 and its 200 day moving average is $28.74. Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.08. The company had revenue of $3.71 million during the quarter, compared to analyst estimates of $3.38 million. Acceleron Pharma had a negative net margin of 229.77% and a negative return on equity of 30.75%. Acceleron Pharma’s revenue was down 79.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 EPS. Equities analysts forecast that Acceleron Pharma will post ($2.60) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/19/acceleron-pharma-inc-xlrn-given-buy-rating-at-fbr-co.html.

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its position in Acceleron Pharma by 6.3% in the first quarter. Goldman Sachs Group Inc. now owns 503,439 shares of the biopharmaceutical company’s stock worth $13,326,000 after buying an additional 29,634 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Acceleron Pharma during the first quarter worth approximately $4,837,000. Platinum Investment Management Ltd. acquired a new position in Acceleron Pharma during the first quarter worth approximately $1,154,000. Tudor Investment Corp ET AL boosted its position in Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 716 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its position in Acceleron Pharma by 52.5% in the first quarter. Eventide Asset Management LLC now owns 653,900 shares of the biopharmaceutical company’s stock worth $17,309,000 after buying an additional 225,000 shares during the last quarter. Institutional investors and hedge funds own 82.57% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

5 Day Chart for NASDAQ:XLRN

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.